Home » About Chugai U.S.A.

About Chugai U.S.A.

“At CPUSA, we are proud to share in Chugai’s mission and dedication to add exceptional value through the creation of innovative medical products and services to benefit of the medical community and human health around the world.”

Chugai is a pharmaceutical company with a mission to create and deliver innovative products and services for the medical community and human health around the world. Chugai is one of the leading research-based pharmaceutical companies in Japan with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (ePoC) for worldwide market, including U.S. For late-stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties.

Some of Chugai’s global development achievements that exemplify first-in-class/best-in-class include:

  • ACTEMRA® (tocilizumab) – first-in-class IL-6 signal blockade agent for rheumatoid arthritis and other autoimmune diseases
  • ALECENSA® (alectinib) – new generation ALK inhibitor for non-small cell lung cancer, with Breakthrough Therapy designation by the FDA
  • HEMLIBRA® (emicizumab-kxwh) – anti-factor IXa/X bispecific antibody, novel concept treatment for hemophilia A (co-development with Roche) with Breakthrough Therapy designation by the FDA
  • ENSPRING® (satralizumab-mwge) – anti-IL-6 receptor antibody using recycling antibody technology for neuromyelitis optica spectrum disorder.

As a key member of global project teams, we support the planning and execution of global and U.S. clinical programs for Chugai originated innovative new drug candidates. In addition, we conduct market research of US market to establish more sophisticated development plan. We currently have several ongoing development programs, where Chugai is independently pursuing global development of its original products.

The Chugai and Roche Groups

Chugai’s Global Operations

Chugai Pharma U.S.A. is part of the Chugai Group and a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd., one of Japan’s leading research-based pharmaceutical companies. Established in 1925, Chugai Pharmaceutical Co., Ltd. has a 30-year history in biopharmaceuticals and employs over 7,000 specialists.

The Strategic Alliance With Roche

In 2002, Chugai Pharmaceutical Co., Ltd. entered into a strategic alliance with Roche and since then Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, has been a member of the Roche Group.

Home » About Chugai U.S.A.